The Leiden University Medical Center (LUMC) has inaugurated a new center aimed at enhancing and expanding treatment options for patients. This initiative reflects LUMC’s commitment to integrating patient care, research, and education to advance healthcare quality and innovation.
The center’s establishment aligns with LUMC’s strategic plan, which emphasizes the integration of core tasks to foster efficiency, cost savings, and ultimately, improved healthcare outcomes. By focusing on personalized, connecting, and curious core values, LUMC aims to create value for patients and society, fostering collaborations between the center and its environment, patients and caregivers, and between theory and practice.
This development underscores LUMC’s dedication to being a pioneer in healthcare innovation, striving to improve patient outcomes through cutting-edge research and tailored treatments.
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.
𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝘁𝘂𝗿𝗻 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗶𝗻𝘁𝗼 𝗿𝗲𝗮𝗹 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀, 𝗳𝗮𝘀𝘁𝗲𝗿, 𝘀𝗺𝗮𝗿𝘁𝗲𝗿, 𝗮𝗻𝗱 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿? That’s the question Key Region Leiden is working to answer. Launched on July 7 at Leiden...
Peter Lindenburg winnaar VUURVLIEGEN tijdens Dutch Bio Science Week Den Haag, 4 juli 2025 – Bijna 130 leerlingen van vier basisscholen uit de Leidse regio hebben onderzoeker...